Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADA | P00813 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15165599 | 1.00 | HIF1A (0.46) | HIF1APOLBSLC29A1ENPP1P2RY1 | |
| SCHEMBL15165598 | 0.91 | HIF1A (0.46) | HIF1APOLBENPP1P2RY1ADORA3 | |
| SCHEMBL13239672 | 0.91 | HIF1A (0.46) | HIF1APOLBENPP1P2RY1ADORA3 | |
| SCHEMBL15165602 | 0.88 | HIF1A (0.42) | HIF1APOLBSLC29A1ENPP1P2RY1 | |
| SCHEMBL13239680 | 0.88 | HIF1A (0.42) | HIF1APOLBSLC29A1ENPP1P2RY1 | |
| SCHEMBL13239695 | 0.88 | HIF1A (0.43) | HIF1APOLBSLC29A1ENPP1P2RY1 | |
| SCHEMBL13239675 | 0.88 | HIF1A (0.43) | HIF1APOLBSLC29A1ENPP1P2RY1 | |
| SCHEMBL15165600 | 0.88 | HIF1A (0.43) | HIF1APOLBSLC29A1ENPP1P2RY1 | |
| SCHEMBL13239660 | 0.85 | HIF1A (0.41) | HIF1APOLBSLC29A1ENPP1P2RY1 | |
| SCHEMBL15165603 | 0.85 | HPGD (0.43) | HIF1ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | HIF1A 3959/4885POLB 255/4885SLC29A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.